RaRE-TS
Project data
Project financing: 16 880 726,88 PLN (including financing for UMED: 3 611 233,02 PLN), financed by the Medical Research Agency (ABM)
Project description:
The aim of the project is to evaluate the efficacy, tolerability and safety of rapamycin as add-on therapy to antiepileptic drugs in patients with drug-resistant epilepsy associated with tuberous sclerosis. In addition, the RaRE-TS study will prospectively analyse molecular, electrophysiological and neuroimaging biomarkers of epileptogenesis and oncogenesis.
The project is being carried out in a consortium with the Institute – Pomnik “Children’s Health Centre” as leader and Medical University of Lodz as partner.
Beneficiary
Consortium composed of:
Institute “Children’s Health Centre Memorial” (Leader)
Medical University of Lodz (Partner)
TRANSITION TECHNOLOGIES SCIENCE SP. Z O.O. (Partner)
Medical University of Warsaw (WUM) (Partner)
Brigham and Women’s Hospital (Partner)
Coordinating Principal Investigator
prof. Katarzyna Kotulska-Jóźwiak, MD, PhD
UMED Site Principal Investigator
prof. Wojciech Młynarski, MD, PhD